Explore
Trendline
Ascendis Pharma Shifts Focus Back to Rare Endocrinology Amid Cancer Strategy Setback
Ascendis Pharma Shifts Focus Back to Rare Endocrinology Amid Cancer Strategy Setback
Read More
Trendline
AN2 Therapeutics to Engage in 2026 Stifel Virtual Targeted Oncology Forum
AN2 Therapeutics to Engage in 2026 Stifel Virtual Targeted Oncology Forum
Read More
Trendline
Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline
Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline
Read More
Trendline
Kanvas Biosciences Secures $48M to Enhance Spatial Biology and Cancer Trials
Kanvas Biosciences Secures $48M to Enhance Spatial Biology and Cancer Trials
Read More
Trendline
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in May 2026
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in May 2026
Read More
Trendline
TORL BioTherapeutics Appoints Aran Maree as CEO to Lead Next Growth Phase
TORL BioTherapeutics Appoints Aran Maree as CEO to Lead Next Growth Phase
Read More
Trendline
AN2 Therapeutics to Present at 2026 Stifel Virtual Targeted Oncology Forum
AN2 Therapeutics to Present at 2026 Stifel Virtual Targeted Oncology Forum
Read More
Trendline
Viridian Therapeutics Prices $350 Million Public Offerings for Expansion
Viridian Therapeutics Prices $350 Million Public Offerings for Expansion
Read More
Trendline
Cytospire Secures $83 Million for Innovative T-Cell Engager Platform
Cytospire Secures $83 Million for Innovative T-Cell Engager Platform
Read More
Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026
Nuvectis Pharma Reports Increased Net Loss in Q1 2026
Read More
Trendline
Curis to Announce Q1 2026 Financial Results and Host Webcast
Curis to Announce Q1 2026 Financial Results and Host Webcast
Read More
Trendline
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Read More
